Fierce Pharma

JULY 18, 2024

Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.

303

303

MedCity News

JULY 18, 2024

The Federal Trade Commission recently released an interim report that details how the practices of pharmacy benefit managers negatively impact patients and pharmacies. Some experts hope for legislative action based on the report. The post The FTC Released a Scathing Interim Report on PBMs. What’s Next? appeared first on MedCity News.

Management 129

Management Patients 129

Fierce Pharma

JULY 18, 2024

As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.

Management 222

Management Biopharma Government 222

MedCity News

JULY 18, 2024

SMS is reevaluating its Star Ratings. Not only do health plans stand to benefit from the new calculations — all healthcare companies and millions of patients will reap the rewards. The post What the Medicare Quality Rating Change Means for Healthcare Companies — and Patient Health appeared first on MedCity News.

Healthcare 105

Healthcare Healthcare Patients Physicians 105

Advertisement

Fierce Pharma

JULY 18, 2024

After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo | After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo.

Marketing 204

Marketing 204

pharmaphorum

JULY 18, 2024

The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare costs in the US.The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs' alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).

Healthcare 105

Healthcare Healthcare Management 105

MedCity News

JULY 18, 2024

Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). Phathom licensed its flagship product from Takeda Pharmaceutical. The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.

Pharma 102

Pharma Patients FDA Pharmaceutical 102

Fierce Pharma

JULY 18, 2024

Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade. | Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade.

Patients 200

Patients 200

MedCity News

JULY 18, 2024

In addition to increasing medication access for underserved populations, an in-house specialty pharmacy improves patient care and provides opportunities for efficiency and enhancement across hospital operations. The post Specialty Pharmacy: A Sound Strategy to Weather Hospital Financial Storms, Enhance Patient Care appeared first on MedCity News.

Patients 102

Patients Medical 102

Fierce Pharma

JULY 18, 2024

The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death in kidney cancer patients who had tried an im | The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death compared with Fotivda alone in kidney cancer patients who had tried an immune checkpoint inhibitor.

Patients 197

Patients 197

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

JULY 18, 2024

The Salt Lake City health system will pilot NeuroFlow’s behavioral health tech platform and services in five primary care locations in Colorado. The first step is to integrate technology into its Epic EHR but the broader goal is to create the mechanism by which behavioral healthcare can be standardized and measured. The post What Intermountain Health Hopes to Achieve with its New Behavioral Health Partnership appeared first on MedCity News.

Healthcare 98

Healthcare Healthcare 98

Fierce Pharma

JULY 18, 2024

After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its Biomedical Advanced Research and Development Authority (BARDA)-backed Nuzyra w | After its buyout last summer by Novo Holdings and Gurnet Point, Paratek Pharmaceuticals reaffirmed the benefits of its BARDA-backed Nuzyra with a positive post-marketing study.

Marketing 191

Marketing Pharmaceutical 191

pharmaphorum

JULY 18, 2024

J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year

108

108

Pharmaceutical Technology

JULY 18, 2024

The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.

FDA 111

FDA 111

Advertisement

Distribution

MedCity News

JULY 18, 2024

The new CMS guidelines represent a transformative moment for Medicare Advantage — here are three ways to be good stewards of taxpayer dollars and create a healthier future for seniors The post Supplemental Benefits are Worth Fighting for to Support Senior Health appeared first on MedCity News.

91

91

pharmaphorum

JULY 18, 2024

Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases

97

97

Pharmaceutical Technology

JULY 18, 2024

Johnson & Johnson has reported a 12.8% decrease in net earnings for Q2 2024, with figures falling to $4.6bn from $5.3bn in Q2 2023.

97

97

pharmaphorum

JULY 18, 2024

Ursula von der Leyen highlights biotech and AI as key sectors in speech as she is re-elected as President of the European Commission

99

99

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaVoice

JULY 18, 2024

With a long elusive HIV cure ever on the horizon, Gilead’s latest long-acting PrEP study shows that every step counts.

98

98

PharmaTimes

JULY 18, 2024

Genentech’s Pulmozyme could also treat other respiratory infections and conditions

102

102

pharmaphorum

JULY 18, 2024

Gilead Sciences' chief medical officer Merdad Parsey has said he will leave the company in early 2025

Medical 89

Medical 89

PharmaTimes

JULY 18, 2024

The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths

Leads 98

Leads 98

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

European Pharmaceutical Review

JULY 18, 2024

What are antibody-drug conjugates and why do they hold potential over other treatment modalities? Antibody drug conjugates (ADCs) are an emerging technology adding significant value to the oncology treatment landscape. They are also increasingly the focus of R&D across the world and remain a modality that is regularly the focus of deals across the industry. 1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduc

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

pharmaphorum

JULY 18, 2024

Discover valuable tips for ensuring on-time tech transfers within budget in this podcast featuring industry experts Frantz Maignan, Grant Brock from Lannett CDMO.

59

59

Pharmaceutical Technology

JULY 18, 2024

hVIVO specialises in human challenge trials for influenza and RSV therapeutic candidates.

81

81

Copyright Clearance Center

JULY 18, 2024

CCC introduced artificial intelligence (AI) re-use rights within its Annual Copyright Licenses (ACL), an enterprise-wide content licensing solution offering rights from millions of works to businesses that subscribe.

52

52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Nixon Gwilt Law

JULY 18, 2024

The New Advanced Primary Care Management HCPCS Codes Under the Proposed Rule, physicians and non-physician practitioners – for example, nurse practitioners (NPs) and physician assistants (PAs) – can order and bill for APCM services. Notably, CMS specifically states that the practitioner who bills for APCM services intends to be responsible for the patient’s primary care and is the continuing focal point for all needed health care services.

Management 52

Management Physicians Medicine Patients 52

Progressive Medical

JULY 18, 2024

EdgeX is a GAMECHANGER PMI is happy to announce a partnership with EdgeX, Inc. to to introduce its EdgeX […] The post Progressive Medical, Inc. Welcomes EdgeX to our Family of Products appeared first on Progressive Medical, Inc.

Medical 52

Medical 52

Pharmaceutical Commerce

JULY 18, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Matthew Walsh, ixlayer’s manager of biopharma, discusses findings of a new physician survey that the company conducted.

Biopharma 52

Biopharma Physicians Pharma Management 52

European Pharmaceutical Review

JULY 18, 2024

A report produced by the Centre for Process Innovation (CPI), alongside CDMO FUJIFILM Diosynth Biotechnologies, has acknowledged “significant” gaps in the UK skills and workforce for RNA therapeutics. The future workforce could require “at least 150 future capabilities to meet RNA vaccine and treatment demand”, according to the report. To support the manufacturing of RNA medicines, these capabilities include development of new equipment and reagents to increase efficiencies, the report

Manufacturing 52

Manufacturing Medicine Education Training 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization